HCC CONNECT Update from ASCO 2019

MEET THE EXPERTS ALL PROGRAMMES DEVELOPED COLLABORATIONS CONTACT

HCC CONNECT Update from ASCO 2019

Prof. James Harding

HCC CONNECT has summarised the highlights from ASCO 2019 for you

Prof. James Harding

Medical Oncologist

Memorial Sloan Kettering Cancer Center

United States (US)

Biography Disclosures

Prof. James Harding

Medical Oncologist

Memorial Sloan Kettering Cancer Center

United States (US)

Dr James Harding is a board-certified medical oncologist at Memorial Sloan Kettering Cancer Center in New York, USA. He specializes in caring for people with liver cancer, gallbladder cancer, and bile duct cancer. His primary goal is to provide the best possible treatment and individualized care for people with these diseases. In his research, he is trying to find new, effective therapies for gastrointestinal cancer, particularly primary liver and bile duct tumors. For example, he is working on ways to use a patient’s own immune system to fight cancer (immunotherapy). In addition, Dr Harding is investigating strategies to block specific cellular pathways that cancer uses to grow. He has helped develop and lead numerous national and international clinical trials of these new cancer therapies for patients with liver, bile duct cancers, and other solid tumors. Dr Harding’s research and training has been supported by the American Society of Clinical Oncology, the National Comprehensive Cancer Network, the National Institutes of Health, the American Association for Cancer Research, and the Howard Hughes Medical Institute. His work has been published in the New England Journal of Medicine, Nature, Nature Medicine, the Journal of Clinical Oncology, Cancer Discovery, Clinical Cancer Research, and Cancer. Relevant publications Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, Ly M, Shia J, Hechtman JF, Kundra R, El Dika I, Do RK, Sun Y, Kingham TP, D'Angelica MI, Berger MF, Hyman DM, Jarnagin WR, Klimstra DS, Janjigian YY, Solit DB, Schultz N, Abou-Alfa GK. Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next Generation Sequencing for Matching Patients to Targeted and Immune Therapies. Clinical Cancer Research 2018. OCT 29 Harding JJ, Lowery MA, Shih AH, Schvartzman JM, Hou S, Famulare C, Patel M, Roshal M, Do RK, Zehir A, You D, Selcuklu SD, Viale A, Tallman MS, Hyman DM, Reznik E, Finley LWS, Papaemmanuil E, Tosolini A, Frattini MG, MacBeth KJ, Liu G, Fan B, Choe S, Wu B, Janjigian YY, Mellinghoff IK, Diaz LA, Levine RL, Abou-Alfa GK, Stein E, Intlekofer AM. Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition. Cancer Discov 2018 Oct 24. Harding JJ, Do RK, Dika IE, Hollywood E, Uhlitskykh K, Valentino E, Wan P, Hamilton C, Feng X, Johnston A, Bomalaski J, Li CF, O'Reilly EM, Abou-Alfa GK. A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies. Cancer Chemother Pharmacol 2018 Sep;82(3):429-440 Harding JJ, Abu-Zeinah G, Chou JF, Owen DH, Ly M, Lowery MA, Capanu M, Do R, Kemeny NE, O'Reilly EM, Saltz LB, Abou-Alfa GK. Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma. J Natl Compr Canc Netw 2018 Jan;16(1):50-58. Harding JJ, El Dika I, Abou-Alfa GK. Immunotherapy in hepatocellular carcinoma: Primed to make a difference? Cancer 2016 Feb 1;122(3):367-77.

Prof. James Harding has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bristol Myers, Eisai and Eli Lilly

time | open 5 min | 2019

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

download resources

Download the slides

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

Liver Cancer by Dr. James J. Harding, Memorial Sloan Kettering Cancer Center, New York, USA

HCC CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer, AstraZeneca and from Eisai Europe Limited.

Other programmes of interest

Dr Elisa Agostinetto

Prof. Valentina Guarneri

Interactive patient case

15 min

Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Meta...

Sep 2023

Prof. Chee-Kiat Tan

Publication

5 min

Surveillance and Diagnosis of HCC in Asia: Poster Presentation at...

Sep 2023

Assoc. Prof. Gerald Prager

Video

4 min

Long-term Response in Advanced Colorectal Cancer

Sep 2023

Prof. Dr Jeroen Dekervel

Dr Amit Singal

Podcast

29 min

A New Era in Treating Patients with Advanced HCC

Sep 2023

Dr Jaume Capdevila

Asst. Prof. Mauro Cives

Micro learning

30 min

Accreditation: EACCME

Recognising, Diagnosing and Managing Neuroendocrine Tumours

Aug 2023

Acromegaly and Neuroendocrine Tumours Global Survey

Publication

15 min

Acromegaly and Neuroendocrine Tumours Global Survey

Aug 2023

Prof. Shaheenah Dawood

Assoc. Clinical Professor Rena Callahan

Podcast

74 min

Oral SERDs in ER+ Breast Cancer

Aug 2023

Dr Tracy L Stockley

Prof. David Hong

Podcast

24 min

An Introduction to Molecular Testing

Jul 2023

Dr Neal Shore

Dr Andrew J. Armstrong

Video

10 min

Clinical Implementation of Testing and PARPi as Monotherapy or in...

Aug 2023

Janet Forgenie

Video

3 min

Nursing Support for mCRPC Patients During Radiopharmaceutical Tre...

Jul 2023

Prof. Andrea Sartore-Bianchi

Video

5 min

Conference Update: ASCO and WCGIC 2023

Jul 2023

Dr Sara Tolaney

Dr Aditya Bardia

Prof. Frédérique Penault-Llorca

Video

71 min

Accreditation: EACCME

New Oral Endocrine Therapy Options for Patients with Advanced or ...

Jul 2023

Other programmes developed by Prof. James Harding

Prof. James Harding

Medical Oncologist

Memorial Sloan Kettering Cancer Center

United States (US)

Prof. Sammy Saab

Prof. James Harding

Podcast

24 min

Podcast: Advanced HCC and not eligible for IO - what are the trea...

Mar 2023

Prof Richard Finn

Dr Mohamed Bouattour

Prof. James Harding

And others...

E-learning

83 min

Accreditation: EACCME

Appropriate selection of patients for 1st line monotherapy in adv...

Feb 2022

Prof. James Harding

Podcast

15 min

Update on key HCC data presented at ASCO GI and EASL-LCS 2022

Feb 2022

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.